ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial.
F
F
Wenz
Y
Y
Abo-Madyan
G
G
Welzel
F A
FA
Giordano
D000328:Adult; D006801:Humans; D008875:Middle Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002423:Cause of Death; D059248:Chemoradiotherapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D015182:Lymphatic Irradiation; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000401:mortality / Q000517:prevention & control; D012307:Risk Factors; D014481:United States; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015337:Multicenter Studies as Topic
D001761:Bleomycin; D003606:Dacarbazine; D004317:Doxorubicin; D014747:Vinblastine